Advertisement

Journal of Neuro-Oncology

, Volume 100, Issue 3, pp 489–490 | Cite as

MGMT promoter methylation status in anaplastic meningiomas

  • Benjamin Brokinkel
  • Bernhard R. Fischer
  • Susanne Peetz-Dienhart
  • Heinrich Ebel
  • Abolghassem Sepehrnia
  • Burckhard Rama
  • Friedrich K. Albert
  • Walter Stummer
  • Werner Paulus
  • Martin Hasselblatt
Letter to the Editor

Keywords

Meningioma Methylation Status Temozolomide Astrocytic Tumor MGMT Promoter Methylation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Perry A, Louis DN, Scheithauer BW, Budka H, von Deimling A (2007) Meningiomas. In: Louis D, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system. IARC, Lyon, pp 164–172Google Scholar
  2. 2.
    Modha A, Gutin PH (2005) Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 57:538–550CrossRefPubMedGoogle Scholar
  3. 3.
    Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127–4136CrossRefPubMedGoogle Scholar
  4. 4.
    de Robles P, McIntyre J, Kalra S, Roldan G, Cairncross G, Forsyth P, Magliocco T, Hamilton M, Easaw J (2008) Methylation status of MGMT gene promoter in meningiomas. Cancer Genet Cytogenet 187:25–27CrossRefPubMedGoogle Scholar
  5. 5.
    Bello MJ, Aminoso C, Lopez-Marin I, Arjona D, Gonzalez-Gomez P, Alonso ME, Lomas J, de Campos JM, Kusak ME, Vaquero J, Isla A, Gutierrez M, Sarasa JL, Rey JA (2004) DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. Acta Neuropathol 108:413–421CrossRefPubMedGoogle Scholar
  6. 6.
    Chamberlain MC, Tsao-Wei DD, Groshen S (2004) Temozolomide for treatment-resistant recurrent meningioma. Neurology 62:1210–1212PubMedGoogle Scholar
  7. 7.
    Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, Giebel B, Wischhusen J, Reifenberger G, Hau P, Beier CP (2008) Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68:5706–5715CrossRefPubMedGoogle Scholar
  8. 8.
    Hasselblatt M, Mühlisch J, Wrede B, Kallinger B, Jeibmann A, Peters O, Kutluk T, Wolff JE, Paulus W, Frühwald MC (2009) Aberrant MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation in choroid plexus tumors. J Neurooncol 91:151–155CrossRefPubMedGoogle Scholar
  9. 9.
    Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6:39–51CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Benjamin Brokinkel
    • 1
  • Bernhard R. Fischer
    • 2
  • Susanne Peetz-Dienhart
    • 1
  • Heinrich Ebel
    • 3
  • Abolghassem Sepehrnia
    • 4
  • Burckhard Rama
    • 5
  • Friedrich K. Albert
    • 5
  • Walter Stummer
    • 2
  • Werner Paulus
    • 1
  • Martin Hasselblatt
    • 1
  1. 1.Institute of NeuropathologyUniversity Hospital MünsterMünsterGermany
  2. 2.Department of NeurosurgeryUniversity Hospital MünsterMünsterGermany
  3. 3.Department of NeurosurgerySt. Barbara-Klinik HammHammGermany
  4. 4.Department of NeurosurgeryClemens-Hospital MünsterMünsterGermany
  5. 5.Department of NeurosurgeryParacelsus ClinicOsnabrückGermany

Personalised recommendations